GILD · News · 20260911N

Litigation and Legal Risk

GILEAD SCIENCES, INC. · 2026-09-11 · Importance 47 · Surprise 60 · In source text

The Fourth Circuit Court of Appeals upheld a preliminary injunction blocking the importation and sale of foreign-market Gilead-branded HIV medications in the United States. The court found that the foreign versions were materially different from the U.S.-marketed drugs, supporting Gilead’s trademark-violation and unfair-competition claims. The ruling protects Gilead’s Biktarvy revenue and creates a favorable precedent against similar drug-importation programs. Pricing pressure from employer health plans seeking lower-cost alternatives is expected to continue.

Key facts

• A federal appeals court ruling upheld a preliminary injunction blocking the importation and sale of foreign-market Gilead-branded HIV medications in the U.S. source
• The appeals court decision protects GILEAD SCIENCES, INC.'s Biktarvy revenue by blocking import programs for foreign-market versions of its HIV medications. source
• The Fourth Circuit Court of Appeals found that the foreign versions of GILEAD SCIENCES, INC.'s HIV drugs were materially different from the U.S.-marketed drugs, supporting Gilead's claims of trademark violation and unfair competition. source

Impact estimates